The strong product sales of this drug in the Japanese market demonstrate not only the clinical dependence on ART-123, but also its market potential, said Mr. Naoyuki Ono, President and CEO of AKP America.. AKP America commences Artwork-123 Phase 3 trial in serious sepsis patients with coagulopathy Asahi Kasei Pharma America Corp. The Stage 3 trial follows an effective 750-individual randomized, double-blind, placebo-controlled Phase 2b research that assessed the efficacy and safety of ART-123. Inder Kaul, AKP America's President of Product Development and CMO, and the medical monitor for the Phase 3 study. A very clear clinical need exists because of this patient people, and I believe that ART-123 is the first truly promising drug candidate that has emerged recently for this difficult indication.Sunita Tandulwadkar.. Affymetrix launches new Axiom myDesign TG Arrays for targeted genotyping market Affymetrix, Inc. This most recent advancement allows researchers to design custom made arrays to genotype 1,500 to 2.6 million markers per sample and rapidly transition from genome-wide scans to specific disease analyses with different experimental approaches on the same platform. ‘Axiom myDesign TG Arrays can help researchers to quickly evaluate interesting variants from their GWAS, sequencing and applicant gene initiatives without limiting the true number of markers in their study,’ stated Andy Last, Chief Commercial Officer of Affymetrix.